Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax—one of the most common forms of malaria.
Pliant Therapeutics has raised a healthy $62 million series B to help fund its proof of concept tests across a range of scarring diseases.
AMPLEXOR Life Sciences: Helping Life Sciences Firms Optimize Routine Document Production
Urovant filed to raise $150 million in its IPO, which will push the company's lead asset through the clinic in a pair of indications.
New HIV treatments could target a molecule called IP6 to render the virus vulnerable to the immune system.
The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need…
Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.
Modus Therapeutics raised over 140 million Swedish krona, or about $15.7 million, to advance clinical studies of sevuparin in sickle cell disease.
Celgene has raised the top dose and expanded its trial of Bluebird Bio myeloma CAR-T bb2121 but still thinks it’s on course for approval in 2020.
The CFO/COO departed months after he was implicated in a scandal that engulfed his former employer.
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.